Abstract:Background: Genetic variants such as inactivating mutation in the bone morphogenetic protein receptor 2 (BMPR2) gene account for approximately 15-20% of the etiology of idiopathic pulmonary arterial hypertension (IPAH). Increasing evidence indicates the existence of other IPAH susceptibility genes. Methods: The whole-genome sequencing was performed in a discovery cohort including 42 IPAH patients who are lacking BMPR2 mutations. Putative IPAH genes were validated in an independent cohort that included 188 IPAH patients and 968 healthy controls. Functional assessments were conducted to analyze the effects of candidate genetic variants on transcript splicing, enzymatic activity and function. Results: An enrichment of rare variants in the gene encoding prostacyclin synthase (PTGIS) was initially identified by the whole-genome sequencing. The association of PTGIS rare variants with IPAH was confirmed in the replication cohort. In total, fourteen patients (6.1%) were heterozygous for three PTGIS rare variants, including one splice-site variant (c.521 1G>A) and two missense variants (R252Q, A447T). These rare variants conferred a 7.8-fold greater risk of IPAH (95% confidence interval (CI), 3.2 to 18.8; P=5 x 10-6). Inhaled iloprost induced more significantly decrease of pulmonary vascular resistance (P=0.001) and increase of cardiac index (P< 0.001) in patients with PTGIS variants than those without. The mini-gene assay indicated that the c.521 1G>A variant resulted in aberrant mRNA transcripts. The functional studies showed that the two missense variants caused a decrease in prostacyclin production and increased cell death in pulmonary microvascular endothelial cells. Conclusions: We have identified three loss-of-function rare variants in the PTGIS gene from two independent IPAH cohorts. The genetic variants of PTGIS predispose pulmonary vascular responses to the iloprost stimulation and cause deleterious effects. These results provide a novel finding that PTGIS rare variants are involved in the pathogenesis of IPAH. Funding: The work was supported by the following grants: the Beijing Natural Science Foundation (7181009, 7172180), the National Natural Science Foundation of China (81320108005), the National Science Fund for Distinguished Young Scholars (81425002), CAMS Innovation Fund for Medical Sciences (2016-I2M-1-002, 2016-I2M-4-003), the National Key Research and Development Program of China (2016YFC0901502), Sanming Project of Medicine in Shenzhen-Professor Zhi-Cheng Jing's Group for Precise Medicine Research in Thrombosis and Vascular Disease (SZSM201502001) , and the fund from State Key Laboratory of Cardiovascular Disease (2016-kf04, 2018ZR-02). Declaration of Interest: The authors declare no competing financial interests.Ethical Approval: The study protocol was approved by the ethics committees of Shanghai Pulmonary Hospital and FuWai Hospital. The participants, who were all of Chinese Han ancestry, provided written informed consent.

New Insights on Unique Therapeutic Potentialities of Prostacyclin and Prostacyclin Synthase

Prostacyclin Synthase Deficiency Leads to Exacerbation or Occurrence of Endothelium-Dependent Contraction and Causes Cardiovascular Disorders Mainly via the Non-TxA2 Prostanoids/TP Axis

Engineered endothelial progenitor cells that overexpress prostacyclin protect vascular cells.

Microsomal prostaglandin E2 synthase-1 and its inhibitors: Molecular mechanisms and therapeutic significance

Molecular recognition and activation of the prostacyclin receptor by anti-pulmonary arterial hypertension drugs

Abstract 18215: Prostacyclin Secretion from Stably Engineered Rat CD45-VEGFR2+ Endothelial Progenitor Cells Preserves Potassium Channel Activity of Human Smooth Muscle Cells under Hypoxia

An Update of Microsomal Prostaglandin E Synthase-1 and PGE2Receptors in Cardiovascular Health and Diseases

Targeting Microsomal Prostaglandin E Synthase 1 to Develop Drugs Treating the Inflammatory Diseases.

Prostacyclin Mitigates Renal Fibrosis by Activating Fibroblast Prostaglandin I 2 Receptor.

Plant-derived mPGES-1 inhibitors or suppressors: A new emerging trend in the search for small molecules to combat inflammation.

Prostacyclin Facilitates Vascular Smooth Muscle Cell Phenotypic Transformation Via Activating TP Receptors when IP Receptors Are Deficient.

Molecular Mechanisms Regulating the Vascular Prostacyclin Pathways and Their Adaptation during Pregnancy and in the Newborn

The Translational Therapeutics of Prostaglandin Inhibition in Atherothrombosis

Prostaglandin synthases: Molecular characterization and involvement in prostaglandin biosynthesis

Therapeutic Potential of Hematopoietic Prostaglandin D2 Synthase in Allergic Inflammation

963 Prostacyclin Regulates NADPH Oxidase 4 in Human Endothelial CELLS THEREBY Promoting Cytoprotection

Competitive Enzymatic Interactions Determine the Relative Amounts of Prostaglandins E2 and D2

Prostaglandins in the Pathogenesis of Kidney Diseases

Prostanoids receptors signaling in different diseases/cancers progression.

PTGIS is a Novel Susceptibility Gene for Pulmonary Arterial Hypertension

Increased Prostacyclin Levels Inhibit the Aggregation and Activation of Platelets Via the Pi3k-Akt Pathway in Prolonged Isolated Thrombocytopenia after Allogeneic Hematopoietic Stem Cell Transplantation